Core Viewpoint - Guangdong Boma Medical Technology Co., Ltd. has applied for listing on the Shenzhen Stock Exchange's ChiNext board, with a fundraising target of 1.7 billion yuan, and is recognized as a leading provider of complex vascular disease intervention solutions globally [1][2]. Company Overview - Boma Medical specializes in the research, production, and global sales of high-performance vascular interventional medical devices, holding a leading position in the domestic market for vascular balloon catheters [1][2]. - The company has developed a comprehensive product matrix with over 50 product series, covering key areas such as coronary intervention, peripheral intervention, neuro intervention, blood dialysis pathways, and interventional accessories [1][2]. Research and Production - Boma Medical has established five R&D centers and laboratories globally, along with four production bases to ensure high-quality supply and scalability [1][2]. - The company has a strong focus on innovation, with significant R&D investments and a well-structured talent team, leading to multiple global breakthroughs in product technology and core processes [2]. Market Presence - The company's products are marketed in over 100 countries and regions, serving thousands of hospitals and medical centers worldwide, thereby establishing a strong brand image in the vascular interventional medical device market [2]. - Boma Medical has adopted a three-pronged business strategy of "innovation + scalability + internationalization," positioning itself as a significant player in the global vascular intervention industry [2]. Financial Performance - For the fiscal years 2022 to 2025, Boma Medical reported revenues of approximately 207 million yuan, 335 million yuan, 460 million yuan, and 303 million yuan respectively, with net profits of -36.06 million yuan, 25.99 million yuan, 76.78 million yuan, and 35.65 million yuan [3][4]. - As of June 30, 2025, the total assets of the company reached approximately 1.04 billion yuan, with a debt-to-asset ratio of 35.38% [4]. Market Share - According to Frost & Sullivan, Boma Medical holds a 9.6% market share in the Chinese coronary balloon dilation catheter market, ranking fourth overall and first among domestic brands [3]. - The company also holds a 4.7% market share in the Chinese peripheral artery balloon dilation catheter market, ranking fifth [3].

Group 1 - The core stock price of Sino Medical reached 33.38 yuan as of August 25, 2025, with an increase of 0.68 yuan, representing a rise of 2.08% [1] - The trading volume on that day was 2.307 billion yuan, with a turnover rate of 16.47% [1] - Sino Medical operates in the medical device industry, focusing on the research, production, and sales of high-end interventional medical devices, including coronary stents and balloon catheters [1] Group 2 - The company's subsidiary, Sino Shenchang Medical Technology Co., Ltd., recently received a registration certificate from the National Medical Products Administration for a disposable microcatheter, which is suitable for neurovascular operations [1] - The registration certificate for the microcatheter is valid until August 21, 2030 [1] - For the first half of 2025, the company reported revenue of 240 million yuan and a net profit attributable to the parent company of 13.84 million yuan [1] Group 3 - On August 25, 2025, the net outflow of main funds was 107 million yuan, with a cumulative net outflow of 1.454 billion yuan over the past five days [2]

Group 1 - The stock price of Sino Medical reached 30.40 yuan as of August 14, 2025, marking a 3.05% increase from the previous trading day [1] - The trading volume on that day was 2.26 billion yuan, with a turnover rate of 18.55% [1] - Sino Medical specializes in the research, production, and sales of cardiovascular interventional medical devices, including coronary stents and balloon catheters [1] Group 2 - A subsidiary of Sino Medical recently received recognition from the U.S. Food and Drug Administration (FDA), which has generated market interest in its potential applications in the field of neurovascular intervention [1] - On August 14, the net inflow of main funds was 164 million yuan, accounting for 1.3% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds was 143 million yuan [1]

Group 1 - The stock price of Sino Medical reported at 14.19 yuan as of August 6, 2025, down by 2.54% from the previous trading day [1] - The trading volume on that day was 119,538 hands, with a transaction amount of 171 million yuan [1] - Sino Medical operates in the medical device industry, focusing on the research, production, and sales of high-end interventional medical devices, including cardiovascular interventional devices like stents and balloon catheters [1] Group 2 - The company's subsidiary, Sino Shenchang, specializes in the development of products in the neurointerventional field [1] - Sino Shenchang's COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter have received breakthrough medical device designation from the FDA [1] - This product is the first in FDA history for the treatment of intracranial atherosclerotic stenosis and the first domestically produced neurointerventional device to receive such designation [1] Group 3 - On the funding flow side, there was a net outflow of 28.91 million yuan from main funds on that day, accounting for 0.49% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds reached 33.18 million yuan, representing 0.56% of the circulating market value [1]